title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
Stocks That Hit 52-Week Lows On Wednesday,20220511T162815,https://www.benzinga.com/markets/options/22/05/27141482/52-weeks-high-and-low-article,PSTX,0.006905,Neutral,0.009901
Stocks That Hit 52-Week Lows On Friday,20220506T160650,https://www.benzinga.com/markets/options/22/05/27050916/52-weeks-high-and-low-article,PSTX,0.005467,Neutral,0.014495
Stocks That Hit 52-Week Lows On Thursday,20220428T193101,https://www.benzinga.com/markets/options/22/04/26872967/52-weeks-high-and-low-article,PSTX,0.00644,Neutral,-0.010025
79 Biggest Movers From Yesterday,20220608T080800,https://www.benzinga.com/news/22/06/27602286/79-biggest-movers-from-yesterday,PSTX,0.060168,Neutral,0.001979
Why Is Yellow Trading Higher By 33%: Here Are 48 Stocks Moving Premarket,20220804T105117,https://www.benzinga.com/news/22/08/28349800/why-is-yellow-trading-higher-by-33-here-are-48-stocks-moving-premarket,PSTX,0.059562,Neutral,-0.136002
U.S. Stocks Are Trading Higher; ISM Services Index Rises Higher Than Expected,20220803T143450,https://www.benzinga.com/news/earnings/22/08/28333657/u-s-stocks-are-trading-higher-ism-services-index-rises-higher-than-expected,PSTX,0.127119,Somewhat-Bullish,0.246215
Stocks That Hit 52-Week Lows On Tuesday,20220426T174457,https://www.benzinga.com/markets/options/22/04/26818122/52-weeks-high-and-low-article,PSTX,0.00928,Neutral,0.001023
Stocks That Hit 52-Week Lows On Friday,20220422T162629,https://www.benzinga.com/markets/options/22/04/26764450/52-weeks-high-and-low-article,PSTX,0.012589,Neutral,-0.024202
"Poseida Therapeutics, Inc.  ( PSTX )  Hits Fresh High: Is There Still Room to Run?",20241213T141503,https://www.zacks.com/stock/news/2383276/poseida-therapeutics-inc-pstx-hits-fresh-high-is-there-still-room-to-run,PSTX,0.791876,Bullish,0.542984
"Poseida Therapeutics, Inc.  ( PSTX )  Hit a 52 Week High, Can the Run Continue?",20241127T141507,https://www.zacks.com/stock/news/2375920/poseida-therapeutics-inc-pstx-hit-a-52-week-high-can-the-run-continue,PSTX,0.796657,Bullish,0.503135
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, ZUO, PSTX on Behalf of Shareholders - Barnes Gr  ( NYSE:B ) , Poseida Therapeutics  ( NASDAQ:PSTX ) ",20241210T161956,https://www.benzinga.com/pressreleases/24/12/g42418150/shareholder-investigation-halper-sadeh-llc-investigates-b-zuo-pstx-on-behalf-of-shareholders,PSTX,0.102013,Somewhat-Bullish,0.220199
"$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of B, PSTX, and ZUO",20241210T145251,https://www.benzinga.com/pressreleases/24/12/g42415284/hareholder-investigation-the-m-a-class-action-firm-continues-to-investigate-the-mergers-of-b-pstx-,PSTX,0.338582,Somewhat-Bullish,0.327207
"Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash",20241209T213000,https://www.globenewswire.com/news-release/2024/12/09/2994099/0/en/Roche-commences-tender-offer-for-all-shares-of-Poseida-Therapeutics-Inc-for-9-00-per-share-in-cash-plus-a-non-tradeable-contingent-value-right-for-up-to-4-00-per-share-in-cash.html,PSTX,0.089909,Neutral,0.111952
"BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Pactiv Evergreen Inc.  ( Nasdaq - PTVE ) , Enterprise Bancorp, Inc.  ( Nasdaq Global Select Market - EBTC ) , The Interpublic Group of Companies, Inc.  ( NYSE - IPG ) , Poseida Therapeutics, Inc.  ( Nasdaq - PSTX ) ",20241209T182214,https://www.benzinga.com/pressreleases/24/12/g42396942/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-pactiv-evergr,PSTX,0.070517,Neutral,0.0
"Kuehn Law Encourages PSTX, BERY, PLL, and RKDA Investors to Contact Law Firm - Piedmont Lithium  ( NASDAQ:PLL ) , Berry Global Gr  ( NYSE:BERY ) ",20241209T140700,https://www.benzinga.com/pressreleases/24/12/g42389999/kuehn-law-encourages-pstx-bery-pll-and-rkda-investors-to-contact-law-firm,PSTX,0.101582,Somewhat-Bullish,0.185357
"The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis",20241202T100000,https://www.zacks.com/stock/news/2377440/the-zacks-analyst-blog-highlights-roche-poseida-therapeutics-merck-astrazeneca-and-novartis,PSTX,0.187827,Neutral,0.097997
"Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success",20241129T200000,https://www.zacks.com/stock/news/2377348/pharma-stock-roundup-rhhby-to-buy-pstx-mrk-azn-see-pipeline-success,PSTX,0.191549,Neutral,0.118333
"Should You Buy Poseida Therapeutics, Inc.  ( PSTX )  After Golden Cross?",20241128T145502,https://www.zacks.com/stock/news/2376552/should-you-buy-poseida-therapeutics-inc-pstx-after-golden-cross,PSTX,0.608634,Bullish,0.469652
Wall Street Analysts Think Poseida Therapeutics  ( PSTX )  Could Surge 49.25%: Read This Before Placing a Bet,20241127T145512,https://www.zacks.com/stock/news/2376066/wall-street-analysts-think-poseida-therapeutics-pstx-could-surge-4925-read-this-before-placing-a-bet,PSTX,0.284861,Somewhat-Bullish,0.304053
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PSTX, ZUO, MNTX on Behalf of Shareholders - Manitex International  ( NASDAQ:MNTX ) , Poseida Therapeutics  ( NASDAQ:PSTX ) ",20241127T071925,https://www.benzinga.com/pressreleases/24/11/g42207558/shareholder-investigation-halper-sadeh-llc-investigates-pstx-zuo-mntx-on-behalf-of-shareholders,PSTX,0.104683,Somewhat-Bullish,0.221931
"BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Poseida Therapeutics, Inc.  ( Nasdaq - PSTX ) , Air Transport Services Group, Inc.  ( Nasdaq- ATSG ) , Micropac Industries, Inc.  ( OTC - MPAD ) , Aerovate Therapeutics, Inc.  ( Nasdaq - AVTE ) ",20241126T204511,https://www.benzinga.com/pressreleases/24/11/g42200196/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-poseida-thera,PSTX,0.082677,Neutral,0.0
"Crude Oil Moves Lower; Dick's Sporting Goods Earnings Top Views - Alector  ( NASDAQ:ALEC ) , Dick's Sporting Goods  ( NYSE:DKS ) ",20241126T190645,https://www.benzinga.com/24/11/42198266/crude-oil-moves-lower-dicks-sporting-goods-earnings-top-views,PSTX,0.140076,Somewhat-Bullish,0.151519
"Nasdaq Rises 100 Points; Abercrombie & Fitch Shares Fall After Q3 Results - Alector  ( NASDAQ:ALEC ) , Abercrombie & Fitch  ( NYSE:ANF ) ",20241126T170125,https://www.benzinga.com/24/11/42195268/nasdaq-rises-100-points-abercrombie-fitch-shares-fall-after-q3-results,PSTX,0.150122,Somewhat-Bullish,0.157608
Roche to Acquire CAR-T Cell Therapy Focused Poseida for $1.5B,20241126T155900,https://www.zacks.com/stock/news/2375474/roche-to-acquire-car-t-cell-therapy-focused-poseida-for-15b,PSTX,0.149346,Somewhat-Bullish,0.172397
"US Stocks Mixed; Best Buy Posts Downbeat Earnings - Alector  ( NASDAQ:ALEC ) , Best Buy Co  ( NYSE:BBY ) ",20241126T144818,https://www.benzinga.com/24/11/42191274/us-stocks-mixed-best-buy-posts-downbeat-earnings,PSTX,0.154951,Somewhat-Bullish,0.160656
"Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details - Poseida Therapeutics  ( NASDAQ:PSTX ) , Roche Holding  ( OTC:RHHBY ) ",20241126T140708,https://www.benzinga.com/general/biotech/24/11/42190068/roches-proposed-acquisition-of-poseida-therapeutics-poised-to-establish-new-core-capability-in-ce,PSTX,0.334008,Somewhat-Bullish,0.153346
"Why Poseida Therapeutics Shares Are Trading Higher By 219%; Here Are 20 Stocks Moving Premarket - Alector  ( NASDAQ:ALEC ) , Channel Therapeutics  ( AMEX:CHRO ) ",20241126T102458,https://www.benzinga.com/24/11/42183881/why-poseida-therapeutics-shares-are-trading-higher-by-219-here-are-20-stocks-moving-premarket,PSTX,0.251247,Somewhat-Bullish,0.217306
"Best Buy, HP And 3 Stocks To Watch Heading Into Tuesday - Best Buy Co  ( NYSE:BBY ) , Dell Technologies  ( NYSE:DELL ) ",20241126T074216,https://www.benzinga.com/news/earnings/24/11/42181574/best-buy-hp-and-3-stocks-to-watch-heading-into-tuesday,PSTX,0.377142,Bullish,0.399562
"Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies",20241126T061000,https://www.globenewswire.com/news-release/2024/11/26/2987189/0/en/Roche-enters-into-a-definitive-agreement-to-acquire-Poseida-Therapeutics-including-cell-therapy-candidates-and-related-platform-technologies.html,PSTX,0.068502,Neutral,0.094504
"Poseida Therapeutics, Inc.  ( PSTX )  Is Up 24.70% in One Week: What You Should Know",20241112T170012,https://www.zacks.com/stock/news/2369115/poseida-therapeutics-inc-pstx-is-up-2470-in-one-week-what-you-should-know,PSTX,0.585052,Bullish,0.397259
"Poseida Therapeutics, Inc.  ( PSTX )  Q3 Earnings and Revenues Beat Estimates",20241107T225510,https://www.zacks.com/stock/news/2366868/poseida-therapeutics-inc-pstx-q3-earnings-and-revenues-beat-estimates,PSTX,0.397098,Neutral,0.089597
"MaxCyte Appoints Cynthia Collins to its Board of Directors - DermTech  ( OTC:DMTKQ ) , Certara  ( NASDAQ:CERT ) ",20241015T120500,https://www.benzinga.com/pressreleases/24/10/g41329104/maxcyte-appoints-cynthia-collins-to-its-board-of-directors,PSTX,0.101582,Neutral,0.0
"Poseida Therapeutics, Inc.  ( PSTX )  Reports Q2 Loss, Tops Revenue Estimates",20240805T215508,https://www.zacks.com/stock/news/2316456/poseida-therapeutics-inc-pstx-reports-q2-loss-tops-revenue-estimates,PSTX,0.397098,Neutral,0.073228
"Are You Looking for a Top Momentum Pick? Why Poseida Therapeutics, Inc.  ( PSTX )  is a Great Choice",20240719T160010,https://www.zacks.com/stock/news/2305496/are-you-looking-for-a-top-momentum-pick-why-poseida-therapeutics-inc-pstx-is-a-great-choice,PSTX,0.59016,Bullish,0.426636
"Akoya Biosciences  ( AKYA )  Reports Q1 Loss, Lags Revenue Estimates",20240513T213503,https://www.zacks.com/stock/news/2273138/akoya-biosciences-akya-reports-q1-loss-lags-revenue-estimates,PSTX,0.209365,Neutral,0.0
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology,20240501T130000,https://www.prnewswire.com/news-releases/astellas-and-poseida-therapeutics-enter-into-research-collaboration-and-license-agreement-to-develop-novel-allogeneic-cell-therapies-in-oncology-302133127.html,PSTX,0.081368,Neutral,0.103166
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus,20240417T130000,https://www.prnewswire.com/news-releases/poseida-therapeutics-hosts-gene-therapy-rd-day-highlighting-new-scientific-advancements-and-pipeline-focus-302118861.html,PSTX,0.161277,Neutral,0.123508
Adaptimmune  ( ADAP )  Down on End of Collaboration With Roche,20240415T181200,https://www.zacks.com/stock/news/2255611/adaptimmune-adap-down-on-end-of-collaboration-with-roche,PSTX,0.18046,Somewhat-Bullish,0.197765
"Gene therapy market size to grow by USD 4.61 billion from 2022 to 2027, North America is estimated to contribute 39 ... - PR Newswire",20240318T093600,https://www.prnewswire.com/news-releases/gene-therapy-market-size-to-grow-by-usd-4-61-billion-from-2022-to-2027--north-america-is-estimated-to-contribute-39-to-the-growth-technavio-302090363.html,PSTX,0.033562,Neutral,0.019119
"EQT, Genie Energy And Other Big Stocks Moving Lower On Monday - EQT  ( NYSE:EQT ) ",20240311T143732,https://www.benzinga.com/news/24/03/37589051/eqt-genie-energy-and-other-big-stocks-moving-lower-on-monday,PSTX,0.254307,Bearish,-0.630832
"Poseida Therapeutics, Inc.  ( PSTX )  Reports Q4 Loss, Tops Revenue Estimates",20240307T235503,https://www.zacks.com/stock/news/2237704/poseida-therapeutics-inc-pstx-reports-q4-loss-tops-revenue-estimates,PSTX,0.399204,Neutral,0.100148
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023,20240307T210700,https://www.prnewswire.com/news-releases/poseida-therapeutics-provides-updates-and-financial-results-for-the-fourth-quarter-and-full-year-2023-302083497.html,PSTX,0.167904,Neutral,0.05544
Universal Health Services  ( UHS )  Q4 Earnings and Revenues Top Estimates,20240227T223510,https://www.zacks.com/stock/news/2232698/universal-health-services-uhs-q4-earnings-and-revenues-top-estimates,PSTX,0.202932,Neutral,0.0
"Synthetic Biology Market Set to Hit USD 96.4 Billion by 2033, Riding on a Strong 19.3% CAGR | Market.us",20240129T091538,https://www.benzinga.com/pressreleases/24/01/g36819760/synthetic-biology-market-set-to-hit-usd-96-4-billion-by-2033-riding-on-a-strong-19-3-cagr-market-u,PSTX,0.024005,Somewhat-Bullish,0.17745
"Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key Milestones",20240104T130000,https://www.prnewswire.com/news-releases/poseida-therapeutics-highlights-recent-progress-strategic-priorities-and-anticipated-2024-key-milestones-302025907.html,PSTX,0.049255,Neutral,0.057747
"Poseida Therapeutics' New Treatment For Multiple Myeloma Shows Early Success In Clinical Trial - Roche Holding  ( OTC:RHHBF ) , Roche Holding  ( OTC:RHHVF ) , Roche Holding  ( OTC:RHHBY ) ",20231211T161711,https://www.benzinga.com/general/biotech/23/12/36176776/why-is-cancer-focused-poseida-therapeutics-stock-trading-higher-today,PSTX,0.352223,Somewhat-Bullish,0.252734
Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology  ( ASH )  Annual Meeting,20231210T170000,https://www.prnewswire.com/news-releases/poseida-therapeutics-presents-positive-early-results-from-its-phase-1-trial-of-allogeneic-car-t-p-bcma-allo1-in-relapsed-refractory-multiple-myeloma-at-the-65th-american-society-of-hematology-ash-annual-meeting-302010725.html,PSTX,0.049974,Neutral,0.057728
"Gene therapy market size to grow by USD 4,613.9 million from 2022 to 2027 | Growing research in gene therapy for ... - PR Newswire",20231201T073500,https://www.prnewswire.com/news-releases/gene-therapy-market-size-to-grow-by-usd-4-613-9-million-from-2022-to-2027--growing-research-in-gene-therapy-for-cvds-and-orphan-diseases-is-the-major-market-trend--technavio-302002646.html,PSTX,0.048523,Neutral,0.017903
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023,20231109T210500,https://www.prnewswire.com/news-releases/poseida-therapeutics-provides-updates-and-financial-results-for-the-third-quarter-of-2023-301983952.html,PSTX,0.099148,Neutral,0.043856
"Gene Therapy Market size to grow by USD 4.61 billion from 2022 to 2027, North America to account for 39% of market ... - PR Newswire",20231103T223500,https://www.prnewswire.com/news-releases/gene-therapy-market-size-to-grow-by-usd-4-61-billion-from-2022-to-2027--north-america-to-account-for-39-of-market-growth--technavio-301976707.html,PSTX,0.074692,Neutral,0.0
"NGM Biopharmaceuticals  ( NGM )  Reports Q3 Loss, Misses Revenue Estimates",20231102T212508,https://www.zacks.com/stock/news/2177665/ngm-biopharmaceuticals-ngm-reports-q3-loss-misses-revenue-estimates,PSTX,0.20698,Neutral,0.0
"Poseida Therapeutics, Inc.  ( PSTX )  Expected to Beat Earnings Estimates: Can the Stock Move Higher?",20231102T140043,https://www.zacks.com/stock/news/2177351/poseida-therapeutics-inc-pstx-expected-to-beat-earnings-estimates-can-the-stock-move-higher,PSTX,0.260189,Neutral,0.091154
"All You Need to Know About Poseida Therapeutics, Inc.  ( PSTX )  Rating Upgrade to Buy",20231016T160006,https://www.zacks.com/stock/news/2166628/all-you-need-to-know-about-poseida-therapeutics-inc-pstx-rating-upgrade-to-buy,PSTX,0.360752,Somewhat-Bullish,0.33909
Poseida Therapeutics Announces Leadership Transition,20231009T203000,https://www.prnewswire.com/news-releases/poseida-therapeutics-announces-leadership-transition-301951263.html,PSTX,0.137868,Neutral,0.125048
"CAR T-cell Therapy for Multiple Myeloma Market to Observe Stunning Growth by 2032, Evaluates DelveInsight | Key Companies - Cartesian, Arcellx, Novartis, Bristol-Myers Squibb, CARsgen, Poseida, Juno, CRISPR, bluebird bio",20230925T210100,https://www.prnewswire.com/news-releases/car-t-cell-therapy-for-multiple-myeloma-market-to-observe-stunning-growth-by-2032-evaluates-delveinsight--key-companies---cartesian-arcellx-novartis-bristol-myers-squibb-carsgen-poseida-juno-crispr-bluebird-bio-301937157.html,PSTX,0.037504,Neutral,0.05738
Poseida Therapeutics to Present at Two Upcoming Investor Conferences,20230905T120000,https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-at-two-upcoming-investor-conferences-301915257.html,PSTX,0.514619,Neutral,0.121761
"Poseida Therapeutics, Inc.  ( PSTX )  Reports Q2 Loss, Tops Revenue Estimates",20230808T214013,https://www.zacks.com/stock/news/2133901/poseida-therapeutics-inc-pstx-reports-q2-loss-tops-revenue-estimates,PSTX,0.395012,Neutral,0.070271
Why Are Poseida Therapeutics Shares Moving Higher Today? - Poseida Therapeutics  ( NASDAQ:PSTX ) ,20230807T145554,https://www.benzinga.com/general/biotech/23/08/33601799/why-are-poseida-therapeutics-shares-moving-higher-today,PSTX,0.546745,Bullish,0.388551
Poseida Therapeutics Announces Strategic Investment by Astellas and Provides Business Update,20230807T130100,https://www.prnewswire.com/news-releases/poseida-therapeutics-announces-strategic-investment-by-astellas-and-provides-business-update-301894295.html,PSTX,0.083059,Neutral,0.062736
Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy,20230807T130000,https://www.prnewswire.com/news-releases/astellas-and-poseida-therapeutics-announce-strategic-investment-to-support-poseidas-commitment-to-redefining-cancer-cell-therapy-301894277.html,PSTX,0.08146,Neutral,0.068832
"Axsome Therapeutics  ( AXSM )  Reports Q2 Loss, Tops Revenue Estimates",20230807T121510,https://www.zacks.com/stock/news/2133028/axsome-therapeutics-axsm-reports-q2-loss-tops-revenue-estimates,PSTX,0.210579,Neutral,0.0
"Voyager Therapeutics  ( VYGR )  Reports Q2 Loss, Tops Revenue Estimates",20230803T122516,https://www.zacks.com/stock/news/2131771/voyager-therapeutics-vygr-reports-q2-loss-tops-revenue-estimates,PSTX,0.20698,Neutral,0.0
"Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-CD19CD20-ALLO1, an Allogeneic Dual CAR-T Cell Therapy for B-Cell Malignancies",20230705T120000,https://www.prnewswire.com/news-releases/poseida-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-p-cd19cd20-allo1-an-allogeneic-dual-car-t-cell-therapy-for-b-cell-malignancies-301868955.html,PSTX,0.118452,Neutral,0.042141
Poseida Therapeutics to Join Russell 3000® and Russell 2000® Indexes,20230626T120000,https://www.prnewswire.com/news-releases/poseida-therapeutics-to-join-russell-3000-and-russell-2000-indexes-301861027.html,PSTX,0.116348,Neutral,0.059972
"Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors - Acrivon Therapeutics  ( NASDAQ:ACRV ) ",20230622T200000,https://www.benzinga.com/pressreleases/23/06/g32975171/acrivon-therapeutics-announces-the-appointment-of-seasoned-biopharma-executive-charles-baum-m-d-ph,PSTX,0.049939,Neutral,-0.018902
Poseida Therapeutics to Present at 31st Congress of the International Society on Thrombosis and Haemostasis,20230522T120000,https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-at-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-301829942.html,PSTX,0.221313,Neutral,0.071648
"What Makes Poseida Therapeutics, Inc.  ( PSTX )  a New Buy Stock",20230510T160007,https://www.zacks.com/stock/news/2093644/what-makes-poseida-therapeutics-inc-pstx-a-new-buy-stock,PSTX,0.359014,Bullish,0.36922
"Poseida Therapeutics, Inc.  ( PSTX )  Reports Q1 Loss, Tops Revenue Estimates",20230509T230512,https://www.zacks.com/stock/news/2092883/poseida-therapeutics-inc-pstx-reports-q1-loss-tops-revenue-estimates,PSTX,0.395012,Neutral,0.070271
"Fate Therapeutics  ( FATE )  Reports Q1 Loss, Tops Revenue Estimates",20230503T211507,https://www.zacks.com/stock/news/2089379/fate-therapeutics-fate-reports-q1-loss-tops-revenue-estimates,PSTX,0.205225,Neutral,0.0
"Poseida Therapeutics, Inc.  ( PSTX )  Reports Q4 Loss, Misses Revenue Estimates",20230309T230508,https://www.zacks.com/stock/news/2063850/poseida-therapeutics-inc-pstx-reports-q4-loss-misses-revenue-estimates,PSTX,0.398148,Neutral,0.131476
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2022,20230309T210500,https://www.prnewswire.com/news-releases/poseida-therapeutics-provides-updates-and-financial-results-for-the-fourth-quarter-and-full-year-2022-301768307.html,PSTX,0.061843,Neutral,0.036042
LLY: 5 Best Pharma Stocks to Buy Right Now,20230309T130814,https://stocknews.com/news/lly-tak-cprx-pstx-vygr-nvs-5-best-pharma-stocks-to-buy-right-now/,PSTX,0.154455,Neutral,0.060419
"Immuneering Corporation  ( IMRX )  Reports Q4 Loss, Misses Revenue Estimates",20230306T224505,https://www.zacks.com/stock/news/2062368/immuneering-corporation-imrx-reports-q4-loss-misses-revenue-estimates,PSTX,0.208764,Neutral,0.0
"Here's What Could Help Poseida Therapeutics, Inc.  ( PSTX )  Maintain Its Recent Price Strength",20230215T135006,https://www.zacks.com/stock/news/2054568/heres-what-could-help-poseida-therapeutics-inc-pstx-maintain-its-recent-price-strength,PSTX,0.417995,Bullish,0.385383
"Poseida Therapeutics, Inc.  ( PSTX )  is on the Move, Here's Why the Trend Could be Sustainable",20230127T135007,https://www.zacks.com/stock/news/2045394/poseida-therapeutics-inc-pstx-is-on-the-move-heres-why-the-trend-could-be-sustainable,PSTX,0.411176,Bullish,0.381418
"Recent Price Trend in Poseida Therapeutics, Inc.  ( PSTX )  is Your Friend, Here's Why",20230110T135006,https://www.zacks.com/stock/news/2037286/recent-price-trend-in-poseida-therapeutics-inc-pstx-is-your-friend-heres-why,PSTX,0.419153,Bullish,0.433518
"Poseida Therapeutics Ushers New Era For Gene Therapies, Analyst Initiating Coverage Says - Poseida Therapeutics  ( NASDAQ:PSTX ) ",20230104T195138,https://www.benzinga.com/analyst-ratings/analyst-color/23/01/30279597/poseida-therapeutics-ushers-new-era-for-gene-therapies-analyst-initiating-coverage-,PSTX,0.470894,Somewhat-Bullish,0.195579
"Alibaba, XPeng, Dada Nexus And Some Other Big Stocks Moving Higher On Wednesday - Altus Power  ( NYSE:AMPS ) , American Well  ( NYSE:AMWL ) ",20230104T153819,https://www.benzinga.com/news/23/01/30276087/alibaba-xpeng-dada-nexus-and-some-other-big-stocks-moving-higher-on-wednesday,PSTX,0.24289,Somewhat-Bullish,0.176288
STLA: 4 Stocks Under $30 to Buy Right Now,20221223T135819,https://stocknews.com/news/stla-aci-pstx-cveo-4-stocks-under-30-to-buy-right-now/,PSTX,0.157278,Neutral,0.106121
"Poseida Therapeutics, Inc.  ( PSTX )  Is a Great Choice for 'Trend' Investors, Here's Why",20221215T135005,https://www.zacks.com/stock/news/2029061/poseida-therapeutics-inc-pstx-is-a-great-choice-for-trend-investors-heres-why,PSTX,0.411176,Bullish,0.381418
Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition,20221211T153000,https://www.prnewswire.com/news-releases/poseida-therapeutics-presents-preclinical-data-from-p-fviii-101-gene-therapy-for-hemophilia-a-at-the-64th-ash-annual-meeting--exposition-301699649.html,PSTX,0.143415,Neutral,0.09753
Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition,20221211T153000,https://markets.businessinsider.com/news/stocks/poseida-therapeutics-presents-preclinical-data-from-p-fviii-101-gene-therapy-for-hemophilia-a-at-the-64th-ash-annual-meeting-exposition-1031964158,PSTX,0.143415,Neutral,0.09753
"Wall Street Analysts See an 189% Upside in Poseida Therapeutics, Inc.  ( PSTX ) : Can the Stock Really Move This High?",20221206T145508,https://www.zacks.com/stock/news/2025827/wall-street-analysts-see-an-189-upside-in-poseida-therapeutics-inc-pstx-can-the-stock-really-move-this-high,PSTX,0.286193,Bullish,0.368137
"7 Penny Stocks To Watch With Unusual Options Activity, December 2022",20221201T191805,https://pennystocks.com/featured/2022/12/01/7-penny-stocks-to-watch-with-unusual-options-activity-december-2022/,PSTX,0.030178,Neutral,0.044264
"Poseida Therapeutics, Inc.  ( PSTX )  Tops Q3 Earnings and Revenue Estimates",20221110T234510,https://www.zacks.com/stock/news/2017059/poseida-therapeutics-inc-pstx-tops-q3-earnings-and-revenue-estimates,PSTX,0.399204,Neutral,0.013751
Best Penny Stocks To Buy Now? 4 Biotech Stocks To Watch,20221007T180630,https://pennystocks.com/featured/2022/10/07/best-penny-stocks-to-buy-now-4-biotech-stocks-to-watch/,PSTX,0.074692,Neutral,0.045573
Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2022,20220811T200500,https://www.prnewswire.com/news-releases/poseida-therapeutics-provides-updates-and-financial-results-for-the-second-quarter-of-2022-301604618.html,PSTX,0.062488,Neutral,0.017047
Global Engineered T Cells Market Report 2022-2027: Increasing Demand for Innovative Biopharmaceutical Therapies & Recent Advances in CAR-T Cell Engineering Propelling Sector,20220811T124836,https://www.benzinga.com/pressreleases/22/08/g28454185/global-engineered-t-cells-market-report-2022-2027-increasing-demand-for-innovative-biopharmaceutic,PSTX,0.039745,Neutral,0.0
$7.5 Million Bet On This Biotechnology Stock? Check Out These 4 Penny Stocks Insiders Are Buying,20220811T122000,https://www.benzinga.com/trading-ideas/long-ideas/22/08/28453438/7-5-million-bet-on-this-biotechnology-stock-check-out-these-4-penny-stocks-insiders-are-,PSTX,0.260559,Somewhat-Bullish,0.308318
"Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate",20220804T130628,https://www.benzinga.com/general/biotech/22/08/28353376/biotech-daily-amgen-gilead-go-shopping-nod-for-astrazenecas-lynparza-in-early-stage-breast-cancer,PSTX,0.09989,Neutral,-0.040761
Nasdaq Surges Over 300 Points; Moderna Earnings Beat Expectations,20220803T183340,https://www.benzinga.com/news/earnings/22/08/28338722/nasdaq-surges-over-300-points-moderna-earnings-beat-expectations,PSTX,0.0864,Somewhat-Bullish,0.217964
Dow Jumps 350 Points; Crude Oil Drops Over 2%,20220803T160010,https://www.benzinga.com/news/earnings/22/08/28335749/dow-jumps-350-points-crude-oil-drops-over-2,PSTX,0.093108,Somewhat-Bullish,0.221342
"Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial",20220803T141314,https://www.benzinga.com/general/biotech/22/08/28331170/biotech-daily-mercks-two-combo-cancer-trials-miss-main-goal-approval-for-sinovacs-covid-19-shot-f,PSTX,0.147516,Somewhat-Bullish,0.239293
Why Poseida Therapeutics  ( PSTX )  Shares Are Trading Higher Premarket Today,20220803T130207,https://www.benzinga.com/general/biotech/22/08/28330653/poseida-shares-rally-as-roche-takes-next-big-step-into-allogeneic-car-t-field,PSTX,0.488777,Bullish,0.466352
"Poseida Therapeutics, Inc.  ( PSTX )  Reports Q1 Loss, Misses Revenue Estimates",20220512T220509,https://www.zacks.com/stock/news/1923638/poseida-therapeutics-inc-pstx-reports-q1-loss-misses-revenue-estimates,PSTX,0.4232,Neutral,-0.041859
12 Health Care Stocks Moving In Wednesday's Pre-Market Session,20220427T121333,https://www.benzinga.com/trading-ideas/movers/22/04/26835463/12-health-care-stocks-moving-in-wednesdays-pre-market-session,PSTX,0.263231,Neutral,0.005639
"Poseida Therapeutics, Inc.  ( PSTX )  Beats Q4 Earnings and Revenue Estimates",20220310T233504,https://www.zacks.com/stock/news/1880585/poseida-therapeutics-inc-pstx-beats-q4-earnings-and-revenue-estimates,PSTX,0.429151,Neutral,-0.00217
